Are you using colchicine for gout-flare prophylaxis?

Inflammation prophylaxis is a crucial component of the management of gout¹

Inflammation prophylaxis, urate-lowering therapy, and diet

The clinical case for a 6-month course of inflammation prophylaxis with colchicine in chronic gout:

Initiation of urate-lowering therapy may trigger breakthrough gout attacks with inflammation²
Inflammation is a key hallmark of recurrent gout²
In clinical studies, 6 months of inflammation prophylaxis with colchicine has been shown to prevent gout flares better than urate-lowering therapy alone¹

Click here to watch a video about the role of colchicine in gout-flare prophylaxis

Evidence matters: treatment guidelines strongly recommend a 3-6 month course of gout-flare prophylaxis such as colchicine³

Colchicine is thought to work by disrupting the gout inflammatory cascade in 2 key ways⁴

Blocking

NLRP inflammasome activation, caspase-1 activation, IL-1β activation

Colchicine blocks the inflammasome complex that mediates interleukin activation.⁴

IL-1ß: Interleukin-1 beta.

Prevention

By inhibiting polymerization of tubulin into microtubules, colchicine prevents neutrophil activation and migration to sites of inflammation.⁴

Colchicine may block and prevent key mediators of symptoms in gout⁴

Learn about the role of inflammation in gout

Explore why GLOPERBA may be right for your patients

Important Safety Information for GLOPERBA^® (colchicine)

Colchicine 0.6 mg oral solution is contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given GLOPERBA.
Fatal overdoses have been reported with colchicine in adults and children. Keep GLOPERBA out of the reach of children.
Blood dyscrasias, such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia, have been reported with colchicine used in therapeutic doses.
Monitor for toxicity and, if present, consider lowering the dose, temporary interruption, or discontinuation of colchicine.
Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider lowering the dose, temporary interruption, or discontinuation of GLOPERBA.
The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

GLOPERBA 0.6 mg oral solution is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of GLOPERBA for acute treatment of gout flares during prophylaxis has not been studied.

GLOPERBA is not an analgesic medication and should not be used to treat pain from other causes.

You are encouraged to report negative side effects of prescription drugs to the FDA. To report suspected adverse reactions, visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information for GLOPERBA.

References: 1. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12):2429-2432. 2. Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155-165. 3. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. 4. GLOPERBA [package insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; 2019.

Are you using colchicine for gout-flare prophylaxis?

Inflammation prophylaxis is a crucial component of the management of gout1